Clinical Trials Logo
  1. Home
  2. Upper Respiratory Infections
  3. NCT02225912
  4. Details
NCT02225912 Clinical Trial

A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers

Upper Respiratory Infections Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02225912
Other study ID # Previn-C
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 2005
Est. completion date May 2005

Study information
Verified date August 2014
Source BioHealth Technologies Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date May 2005
Est. primary completion date May 2005
Accepts healthy volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subject must provide written informed consent prior to the conduct of any study

- Male or female

- 18-65 years of age

- Inclusive

- Employed by one of seven selected Day Care Centers

Exclusion Criteria:

- Recent symptoms of upper respiratory infection, respiratory disease

- Received medication for colds or allergies within 3 weeks of enrolling

- Had nasal surgery within 2 months of enrolling

- Had a pierced nose or wore nose jewelry

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• PrevinC

Drug:
• placebo

Locations
Country Name City State
United States Sunflower Preschool & Day Care Hialeah Florida
United States Sunflower Preschool Childcare Miami Florida
United States Sunflowers Academy Miami Florida
United States Sunflowers Academy Miami Florida
United States Sunflowers Preschool Childcare Miami Florida
United States Mt Sinai Day Care Miami Beach Florida

Sponsors (1)
Lead Sponsor Collaborator
BioHealth Technologies Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rhinitis The incidence of rhinitis was measured on a weekly basis through evaluation of study diaries. weekly from February 2005 to May 2005, up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT02451163 - DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly Phase 2
Recruiting NCT01971112 - Nutritional Intervention and Respiratory Infections in Older Subjects N/A
Completed NCT01717534 - Children Immune Functions N/A
Completed NCT01728090 - Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections Phase 4
Completed NCT00235703 - Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART) N/A
Completed NCT02232711 - Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting N/A
Completed NCT01731392 - Children Immune Functions(2) N/A
Withdrawn NCT00773435 - Effects of Echinacea in Children N/A
Completed NCT03464279 - Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections N/A
Completed NCT01586962 - Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI Phase 3
Completed NCT01576809 - Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI) Phase 3
Completed NCT00611195 - Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI Phase 4